We have described two cases of Devic's disease patients treated with rituximab with different outcomes. The results indicate that there may be early unresponsiveness in very aggressive cases. Well designed clinical trials are needed to assess treatment effects in such a rare disease.
Centro di Riferimento Regionale Sclerosi Multipla & Neurobiologia Clinica - ASO S. Luigi Gonzaga, Regione Gonzole 10, I-10043, Orbassano (TO), Italy. sclerosi.multipla@sanluigi.piemonte.it
